Fundación MEDINA

Casa
España
Granada
Fundación MEDINA

Discovery of new bioactive compounds and innovative therapies
for unmet medical needs and high-value biotechnological products

MEDINA is an independent and non profit Research Organization developing innovative programs, collaborations and contracts with academic and industrial partners worldwide. MEDINA owns one of the largest Microbial Collections and the most chemically diverse Natural Products Libraries

Our team has unique expertise in natural products microbiology, chemistry and high throughput screening, as well as in early preclinical safety, drug metabolism and bioanalysis. We are currently active in drug discovery programs in infectious diseases (including tuberculosis and parasitic diseases),cancer, neurodegeneration, and rare diseases. Leveraging our unique strengths in high resolution-high throughput analytics and bioanalytics we are collaborating with clinical investigators in translational research programs for biomarker discovery and metabolomic profiling of patient samples. We are currently active in drug and biomarker discovery programs in infectious and neglected diseases cancer, CNS, and rare diseases. MEDINA is a Research Organization established in the Health Sciences Technology Park, Granada (Spain) as a private-public partnership between the Government of Andalucía (Spain), the University of Granada and Merck Sharp and Dohme de España S.A.

24/03/2026

From a conventional enzymatic assay to a high-throughput screening platform in weeks.

Transitioning an optimized in vitro assay from an academic setting to high-throughput screening requires more than just automation; it demands a fundamental redesign of the assay’s robustness.

At Fundación MEDINA, we are experts in developing automated and miniaturized assays starting from your proof-of-concept. We transform your experimental assay into a fully operational, high-throughput platform.

👉 Read below about the experience of Prof. Ruben Martinez-Buey at the University of Salamanca

Universidad de Salamanca Universidad de Granada Junta de Andalucía MSD España

18/03/2026

The evaluation of metabolic stability is a standard procedure in early drug discovery. However, relying solely on disappearance rates often overlooks the formation of active or reactive metabolites. These unidentified species can cause toxicity, leading to late-stage dropout.

At Fundación MEDINA, we offer a comprehensive approach to Metabolite Profiling. Our objective is to provide the chemical evidence necessary to rule out safety risks before moving to regulatory phases.

Analytical Capabilities:

🟢 High-Resolution LC-HRMS: We utilize high-resolution accurate mass technology for the unambiguous identification and quantification of metabolites from both in vitro and in vivo matrices.
🟢 Integrated ADME-Tox: Our service combines systematic workflows with in-depth scientific interpretation of every metabolite profile.

👉For detailed specifications on our LC-MS solutions or to discuss a custom ADME-Tox protocol, please contact our scientific team.

Universidad de Granada Junta de Andalucía MSD España

16/03/2026

🎉 Fundación MEDINA celebra con su paso a la siguiente fase de la Capital Europea de la Cultura 2031.
Desde Fundación MEDINA, entidad que lleva Granada en su ADN, nos sumamos a esta candidatura hace tiempo porque creemos profundamente que la ciencia también es cultura.
Este primer sí es un reconocimiento al trabajo, a la ilusión y al proyecto colectivo que hay detrás. Pero el camino continúa, y nosotros seguimos ahí, apoyando cada paso.

💪 Vamos, Granada. El mejor capítulo aún está por escribirse.
Granada 2031 UNESCO CSIC New Ground Research Fundación Unicaja Diputación de Granada Ayuntamiento de Granada Cámara Comercio Granada Junta de Andalucía MSD España

05/03/2026

Entering regulatory phases with the wrong candidate is a costly mistake. The key to efficiency in Drug Discovery lies in the preliminary phase: Non-GLP Preclinical Research.

At Fundación MEDINA, we offer a flexible and cost-effective approach to Non-GLP Preclinical Studies. Our goal isn't just to generate data, but to generate exploratory knowledge that allows you to refine hypotheses and select the best drug candidate for optimization.

Why choose our Non-Regulatory Preclinical approach?

✅ Smart De-risking: Anticipate toxic/genotoxic effects and potential interactions early, reducing the probability of failure in later stages.

✅ Cost-Efficiency: Because non-GLP studies are more affordable, you can analyze multiple candidates simultaneously to identify the winner based on robust Go/No-Go criteria.

✅ Ethical Innovation: We prioritize in vitro over in vivo models following the 3Rs rule (Replacement, Reduction, Refinement), aligned with RD 1386/2018.

We offer the infrastructure of a large center with the accessibility of a dedicated service provider.
👇 ready to de-risk your candidate? Contact our team for a customized proposal.
https://www.medinadiscovery.com/
Universidad de Granada Junta de Andalucía MSD España

27/02/2026

Ayer en Fundación MEDINA recibimos la visita de los alumnos del Máster en Biología Agraria y Acuicultura de la Universidad de Granada, acompañados por el profesor Alberto Bago, Estación Experimental del Zaidín-CSIC.

Durante la visita, los estudiantes tuvieron la oportunidad de conocer como los avances en biotecnología microbiana que se desarrollan en la Fundación son cruciales para una Agricultura más Sostenible.

🔬 La visita estuvo llena de momentos inspiradores, donde los alumnos pudieron interactuar con nuestros investigadores, plantear preguntas y explorar posibles colaboraciones, ampliando sus horizontes académicos y brindándoles una valiosa perspectiva sobre el impacto real de la investigación e innovación científica en nuestra sociedad.

Universidad de Granada MSD España Junta de Andalucía hashtag

27/02/2026

Tomorrow is Rare Disease Day

While individual rare diseases affect a small number of people, their collective impact is a global health challenge. When each individual disease might only have a few cases around the world, tools like iPSC technology and gene editing become fundamental to generate cell-based models that help understanding the mechanisms underlying rare diseases.

At Fundación MEDINA, we use iPSC-based gene modeling to seek therapeutic options for rare diseases.

Research into rare diseases is not just about the few; it is also about advancing our fundamental understanding of human biology through cutting-edge science.
Universidad de Granada Junta de Andalucía MSD España

26/02/2026

¡En Fundación MEDINA estamos de enhorabuena!
Felices y orgullosos de nuestra investigadora predoctoral, Inmaculada Iáñez García, que ha recibido el premio al mejor TFM de Bioinformática en el celebrado durante las X Jornadas de Bioinformática de la de Granada (UGR) y esponsorizado por Revvity.
Este trabajo combina análisis de imagen de alto contenido con IA para evaluar el efecto de la quimioterapia en modelos 3D de cáncer de mama. Este reconocimiento pone en valor el impacto y la calidad científica de nuestros proyectos y de las nuevas generaciones de investigadores que se están formando en MEDINA.
¡Enhorabuena Inma!
Facultad de Ciencias de la Universidad de Granada Universidad de Granada MSD España Junta de Andalucía

17/02/2026

🚀 New Article Published! Unlocking the Power of Non GLP Preclinical Studies in Drug Discovery

Before a molecule becomes a drug candidate, it must survive one of the most challenging stages in R&D: preclinical evaluation. And this is where non GLP preclinical studies become true game changers.

In our latest article in Laboratory Animals journal, we highlight how early ADME tox studies—flexible, fast, and cost effective—empower teams to:

✨ Screen more candidates in less time
✨ Identify risks before they become expensive failures
✨ Make smarter go/no go decisions
✨ Select the strongest lead with confidence
✨ Reduce animal use by prioritizing in vitro models

These exploratory studies provide a competitive edge, helping organizations optimize resources while increasing the likelihood of success in later development phases.
Backed by insights from the Preclinical Area at Fundación MEDINA, the article also showcases companies offering ready to use models and on demand assays to accelerate discovery.
If your work touches early drug development, pharmacology, biotech innovation, or strategic R&D decisions… this is a must read.

https://www.medinadiscovery.com/wp-content/uploads/2026/02/Preclinical-Studies-and-GoNo-Go-Decision-Criteria-in-Early-Drug-Development.pdf

👉 Elevate your pipeline. Reduce risk. Accelerate innovation.

-tox SECAL, Sociedad Española para las Ciencias del Animal de Laboratorio Confederación de Sociedades Científicas de España (COSCE) Universidad de Granada MSD España Junta de Andalucía

17/02/2026

Last week our doctoral student Gioele Pecin presented a poster at the “Natural Products in the 21st Century” conference in .

The conference, organised by the students of MAGic-MOLFUN doctoral network, took place at the Provinciehuis Vlaams-Brabant venue in Leuven from 9 to 11 February and welcomed important guests from the field of natural products, offering interesting talks on topics ranging from genomics to metabolomics.

In the poster presented at the conference, Gioele explains how he managed to heterologously express the main genes of the biosynthetic cluster of a new fungal natural product in a black yeast host.

The Novo Nordisk Foundation Center for Biosustainability - DTU Danmarks Tekniske Universitet - DTU Fundación MEDINA Eberhard Karls Universität Tübingen European Union Naicons Newcastle University Wageningen University & Research c-LEcta GmbH

16/02/2026

Hoy se reunían los principales representantes de las ciudades candidatas a albergar la de la Agencia Estatal de Salud Pública en un nuevo debate Imprescindible de GranadaDigital.
En Fundación MEDINA estamos directamente relacionados con la salud publica: nos dedicamos a investigar y desarrollar nuevos fármacos para necesidades médicas o retos en salud pública, como la resistencia a antibióticos.

Apoyamos la candidatura de , nuestra ciudad, para albergar la Sede de la Agencia Estatal de Salud Pública.

Universidad de Granada MSD España Junta de Andalucía

16/02/2026

Excited to participate in the IQF Technical-Scientific Symposium in Madrid, March 10th.
Francisco Castillo, researcher at Fundación MEDINA, will present our latest expertise in combining affinity-based screening with orthogonal cell-free workflows, enabling more efficient drug discovery while tackling challenging targets with confidence. Join us to explore new trends in molecular interactions.

Full agenda and registration: https://nanotempertech.com/events/workshops/iqf-technical-scientific-symposium/
NanoTemper Technologies Instituto de Química Física "Blas Cabrera" (IQF-CSIC) Universidad de Granada MSD España Junta de Andalucía

13/02/2026

Participamos en la “Mesa de la Ciencia y la innovación “del Ayuntamiento de Granada, colaborando en la estrategia e impulso de la e como pilares del desarrollo económico de la ciudad de y su entorno.
Fundación MEDINA Universidad de Granada Junta de Andalucía MSD España

Dirección

Parque Tecnológico De La Salud/Avenida Del Conocimiento, 34
Granada
18016

Página web

http://www.medinadiscovery.com/

Notificaciones

Sé el primero en enterarse y déjanos enviarle un correo electrónico cuando Fundación MEDINA publique noticias y promociones. Su dirección de correo electrónico no se utilizará para ningún otro fin, y puede darse de baja en cualquier momento.